Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, John Rose, Michael D. Kaufman et al.|The Lancet Neurology|2010Cited by 300
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gilmore O’Neill, Gavin Giovannoni et al.|The Lancet|2013Cited by 287
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trialJacob Elkins, Mitchell S.V. Elkind, Ih Chang et al.|The Lancet Neurology|2017Cited by 213
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Gilmore O’Neill, Marianne T. Sweetser et al.|The Lancet Neurology|2014Cited by 94